Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

Por Roit, Fabio Da, Engelberts, Patrick J., Taylor, Ronald P., Breij, Esther C.W., Gritti, Giuseppe, Rambaldi, Alessandro, Introna, Martino, Parren, Paul W.H.I., Beurskens, Frank J., Golay, Josée
Publicado no Haematologica (2015)

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Por Overdijk, Marije B, Verploegen, Sandra, Bögels, Marijn, van Egmond, Marjolein, van Bueren, Jeroen J Lammerts, Mutis, Tuna, Groen, Richard WJ, Breij, Esther, Martens, Anton CM, Bleeker, Wim K, Parren, Paul WHI
Publicado no MAbs (2015)

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies

Por van der Horst, Hilma J., Oostindie, Simone C., Cillessen, Saskia. A. G. M., Gelderloos, Anne T., Overdijk, Marije B., Nijhof, Inger. S., Zweegman, Sonja, Chamuleau, Martine E. D., Breij, Esther C. W., Mutis, Tuna
Publicado no Hemasphere (2020)

Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer

Por Koopman, Louise A., Terp, Mikkel G., Zom, Gijs G., Janmaat, Maarten L., Jacobsen, Kirstine, Gresnigt-van den Heuvel, Elke, Brandhorst, Marcel, Forssmann, Ulf, de Bree, Freddy, Pencheva, Nora, Lingnau, Andreas, Zipeto, Maria A., Parren, Paul W.H.I, Breij, Esther C.W., Ditzel, Henrik J.
Publicado no JCI Insight (2019)

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Por van der Horst, Hilma J., de Jonge, A. Vera, Hiemstra, Ida H., Gelderloos, Anne T., Berry, Daniella R. A. I., Hijmering, Nathalie J., van Essen, Hendrik F., de Jong, Daphne, Chamuleau, Martine E. D., Zweegman, Sonja, Breij, Esther C. W., Roemer, Margaretha G. M., Mutis, Tuna
Publicado no Blood Cancer J (2021)

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

Por Engelberts, Patrick J., Hiemstra, Ida H., de Jong, Bart, Schuurhuis, Danita H., Meesters, Joyce, Beltran Hernandez, Irati, Oostindie, Simone C., Neijssen, Joost, van den Brink, Edward N., Horbach, G. Jean, Verploegen, Sandra, Labrijn, Aran F., Salcedo, Theodora, Schuurman, Janine, Parren, Paul W.H.I, Breij, Esther C.W.
Publicado no EBioMedicine (2020)

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

Por Oostindie, Simone C., van der Horst, Hilma J., Lindorfer, Margaret A., Cook, Erika M., Tupitza, Jillian C., Zent, Clive S., Burack, Richard, VanDerMeid, Karl R., Strumane, Kristin, Chamuleau, Martine E. D., Mutis, Tuna, de Jong, Rob N., Schuurman, Janine, Breij, Esther C. W., Beurskens, Frank J., Parren, Paul W. H. I., Taylor, Ronald P.
Publicado no Haematologica (2019)

DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies

Por Oostindie, Simone C., van der Horst, Hilma J., Kil, Laurens P., Strumane, Kristin, Overdijk, Marije B., van den Brink, Edward N., van den Brakel, Jeroen H. N., Rademaker, Hendrik J., van Kessel, Berris, van den Noort, Juliette, Chamuleau, Martine E. D., Mutis, Tuna, Lindorfer, Margaret A., Taylor, Ronald P., Schuurman, Janine, Parren, Paul W. H. I., Beurskens, Frank J., Breij, Esther C. W.
Publicado no Blood Cancer J (2020)